Scholars Central

PerspectivePublished 26 Sep 2022

Impact of pre-existing immunity to influenza on Live-attenuated influenza vaccine

Authors: Tanay Shukla

Nanotechnology Letters

Volume 7 · Issue 5 · Pages 22–23

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Between 2010 and 2016, the Live Attenuated Influenza vaccine (LAIV) demonstrated varied effectiveness against influenza in the United States, leading to a recommendation against its use. In stark contrast, pre-clinical investigations have repeatedly proven that LAIV outperforms inactivated influenza vaccinations against mismatched Influenza Viruses (IIV). This difference in reported vaccination efficacies between pre-clinical and clinical research may be explained in part by the limitations of influenza animal models. The absence of pre-existing immunity in animal models, in particular, has lately emerged as a potential reason for inconsistencies between preclinical and human investigations. The purpose of this article is to discuss the possible influence of pre-existing immunity on LAIV-induced immunogenicity, with a focus on cross-protective immunity.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalNanotechnology Letters
  • SubjectNanotechnology
  • BylineArticles whose byline prints “Tanay Shukla”